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Abstract
Background: The human pathogenic mold Aspergillus fumigatus is able to form a complex biofilm embedded in
extracellular matrix. Biofilms confer antimicrobial resistance and it is well known that aspergillosis is often refractory
to the conventional antifungal therapy. The treatment of biofilm-related infections poses a significant clinical challenge
on a daily basis, promoting the search for new therapeutic agents.
Our aim was to exploit the modulation of sphingolipid mediators as new therapeutic target to overcome antifungal
resistance in biofilm-related infections.
Results: Antifungal susceptibility testing was performed on 20 clinical isolates of Aspergillus fumigatus and one
reference strain (A. fumigatus Af293) according the EUCAST protocol. Sessile MICs were assessed on 24-h preformed-
biofilm by means of XTT-reduction assay. Myriocin (0.25–64 mg/L), a commercial sphingolipid synthesis inhibitor, was
used. The MEC50 value (mg/L) of Myriocin was 8 (range 4–16) for both planktonic and sessile cells.
Drug-induced morphological alterations were analyzed by optical and electron microscopy (TEM) on 24h preformed A.
fumigatus Af293 biofilms.
An evident hyphal damage, resulting in short, stubby, and highly branched hyphae was observed by optical
microscopy. At 24h, TEM studies showed important morphological alterations, such as invaginations of the cell
membrane, modification in the vacuolar system and presence of multilamellar bodies, in some cases within vacuoles.
Conclusions: The direct antifungal activity, observed on both planktonic and sessile fungi, suggests that inhibition of
sphingolipid synthesis could represent a new target to fight biofilm-related A. fumigatus resistance.
Keywords: Fungal infections, Ceramide, Nanocarriers
Background
The ubiquitous environmental mold Aspergillus fumiga-
tus is one of the most common fungal pathogens. The
risk of developing fungal infections is increasing in pa-
tients with underlying debilitating diseases, such as can-
cer, chronic lung diseases, transplantation or immune
system impairment [1, 2].
A. fumigatus can cause a variety of diseases, ranging
from invasive pulmonary aspergillosis and aspergilloma
to allergic syndromes such as allergic rhinitis and
asthma, and allergic bronchopulmonary aspergillosis
(ABPA) [3]. In chronic forms of aspergillosis A. fumiga-
tus has been demonstrated to develop a thick biofilm
that promotes its persistence [3, 4].
Bacteria and fungi are able to secrete polymers that
function as scaffold for biofilm formation. These slime-
embedded microbial communities endow the pathogens
with an intrinsic ability to escape immune-surveillance,
and are also poorly or null penetrable by most of the
antimicrobial drugs [5].
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Antifungal resistance is emerging in Aspergillus species,
and it is becoming a major health problem in biofilm-
related infections. Failure of antifungal treatment can be
due to host factors, to the pharmacokinetic and pharma-
codynamics parameters of the drug or to morphological,
reproductive modalities and biofilm production of the
fungus itself [6, 7].
Due to the common eukaryotic structure of fungi
and humans, a limited number of antifungal drugs is
tolerated by the host and available for therapeutic
purposes, and new targets as well as innovative strat-
egies to overcome primary and biofilm-related resist-
ance are needed.
Several sphingolipid metabolism inhibitors have
been demonstrated to exert a broad-spectrum anti-
fungal activity [8]. Sphingolipids (SPLs) are a class of
molecules with structural and signaling activities
conserved from fungi to humans. Many studies have
demonstrated that sphingolipid mediators or modula-
tors are involved in infection-related mechanisms
[9–11]. Ceramides are the central molecules in SPLs
and glycosphingolipids (GSLs) biosynthesis. The bio-
synthesis of sphingolipids starts with the condensa-
tion of a fatty acyl CoA, usually palmitoyl CoA, with
serine, which is catalyzed by serine palmitoyl trans-
ferase (SPT), a common enzyme in the biosynthetic
pathway of SLPs of both fungal and human cells and
a possible common target of sphingolipid metabolism
inhibitors.
Myriocin is a specific inhibitor of de novo sphingo-
lipid synthesis and its administration to human cells
causes a re-arrangement of the endogenous pools of
sphingolipids and an overall inhibition of proliferation
without triggering cell death. Myriocin was used in re-
search studies to inhibit highly proliferative cancerous
cells with no sign of toxicity for normal cells [12, 13].
Moreover its effect as an immunomodulator/immuno-
suppressant in vivo has been reported but there is no
clear evidence of specific mechanism underlying this
activity of the compound [14].
Nanocarriers lung delivery of Myriocin, a commercial
inhibitor of SPT catalytic activity, has been recently
shown to efficiently reduce the inflammatory milieu in
cystic fibrosis mice, and consequently to reduce the per-
sistence of Pseudomonas aeruginosa infection [15].
In consideration of the opportunistic nature of fun-
gal infection that takes advantage of patient’s pre-
existing inflammatory conditions, and to the strict de-
pendency of fungal survival on SPL synthesis, our
aim was to exploit the Myriocin antifungal activity to
overcome biofilm-related fungal resistance. We here
demonstrate that solid lipid nanocarriers-mediated
Myriocin delivery represents a promising tool in
biofilm-related aspergillosis.
Results
Myriocin in vitro susceptibility testing and time-killing
assay
To assess the direct antifungal activity of Myriocin, we
performed the standard antifungal susceptibility testing
on A. fumigatus conidia.
The minimum effective concentration of Myriocin in-
ducing morphological alteration of A. fumigatus hyphae
(MEC50) was 8 mg/L (range 4–16). The drug-induced al-
terations observed microscopically are shown in Fig. 1b,
and compared to the untreated fungus (panel a).
The time-kill curves performed on the reference strain
Af293 demonstrated that within the 24 h of Myriocin
exposure, there was only a limited concentration-
dependent killing. In fact, the difference to the control
was about 2 log10 CFU/mL for the higher Myriocin con-
centration (Fig. 2).
We then evaluated the antifungal activity of Myriocin
on 24 h preformed A. fumigatus biofilms. The sessile
MIC50, measured by means of XTT-reduction assay after
24 h treatment, was 8 (range 4–16 mg/L).
We also observed a dose-dependent progressive re-
duction of both biomass and metabolic activity of the
biofilms, as determined by CV and XTT assays respect-
ively, in response to different Myriocin concentrations.
Figure 1c, d reports the significant (p < 0.05) reduction
of both parameters.
Effect of Myriocin treatment on fungal preformed
biofilms morphology and structure
To investigate the morphological and structural changes
induced by Myriocin on preformed fungal biofilms, A.
fumigatus Af293 was used for CLSM and TEM micro-
scopic evaluation after 24 h following exposure to 4 mg/L
Myriocin.
Biofilm thickness was measured by CLSM z-
sectioning. The inhibition of sphingolipid de novo
synthesis highly influenced the production of biofilm
biomass in A. fumigatus Af293, with an overall re-
duction of almost 60 % (32 μm ± 1.61 versus 13.4 ±
0.96 μm, P < 0.0001).
In order to develop a strategy for biofilm effective drug
delivery, the use of SLNs as Myriocin carrier was evalu-
ated by means of labeled particles. We demonstrated
that SLNs are able to penetrate the fungal biofilm (Fig. 3),
and to reach the bottom layer of the biofilm within 6 h.
Ultrastructural imaging was performed by TEM ana-
lyses on A. fumigatus Af293 biofilms, treated or not with
Myriocin, at various time points (4, 24 and 48h).
The ultrastructural imaging of A. fumigatus biofilms
treated with Myriocin (4 mg/L) showed that there was a
progressive loss of cell structure both at cell membrane
and at cytoplasmic level (Fig. 4). 4 h after treatment, the
fungal cells already showed some alterations of the inner
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membrane that became irregular in thickness and dens-
ity, while internal organelles like mitochondria were well
preserved (Fig. 4b). After 24 h of Myriocin treatment,
many cells were damaged, showing cell wall detachment
from plasma membrane, invaginations of the plasma
membrane, presence of multilamellar bodies, and re-
duced density of cytosolic matrix. The internal structure
was less definite and showed higher density (Fig. 4c). In
some cases, the hyphae showed a cell wall collapsed
(Fig. 4d). Cytoplasm was clearly degenerated due to high
vacuolization and no organelle was still recognizable.
When Myriocin treatment was prolonged up to 48 h, a
large part of the fungal structure was damaged and dis-
rupted, and many cells looked empty (Fig. 4e).
Effect of Myriocin treatment on fungal sphingolipid
synthesis
To assess the direct activity of Myriocin on sphingolipid
de novo synthesis in fungi, we measured intracellular
phytoceramides content, a key intermediate, of A. fumi-
gatus biofilms in presence or absence of the drug.
Phytoceramide is a key sphingolipid intermediate, main-
tained in a homeostasis concentration in normal condi-
tion or increased and actively signaling upon a variety of
stresses. As expected, we observed a significant decrease
(about 70 %) of phytoceramides level in A. fumigatus
biofilm exposed to Myriocin (Fig. 5).
Discussion
Our study shows that Myriocin exerts a strong antifun-
gal activity against A. fumigatus, by inhibiting conidia
germination, and significantly reduces biofilm metabol-
ism and biomass.
By optical microscope, we were able to demonstrate
that Myriocin led to the presence of aberrant hyphal
structures in A. fumigatus conidia, with increased
branching and reduction in apical hyphal growth. Polar-
ized growth is essential for the morphology of filament-
ous fungi and atypical hyper-branched hyphae are seen
in the presence of active antifungal compounds [16].
In addition, Myriocin exerted antifungal activity against
preformed fungal biofilms by reducing their biomass and
Fig. 1 Effect of Myriocin on A. fumigatus biofilms. Biofilms exposed to Myriocin were characterized by CLSM (20X): (a) untreated biofilm, and (b)
biofilm 24h post-Myriocin (4 mg/L). The drug efficacy was also assessed by measuring the fungal biomass (c), and the biofilm metabolic
activity (d)
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metabolic activity, as clearly shown by the ultrastructural
studies (Fig. 4).
The treatment with the sphingolipid de novo synthesis
inhibitor resulted in a significant disadvantage for A. fumi-
gatus growth. Our hypothesis is that sphingolipid synthe-
sis inhibition acts as a fungistatic agent by affecting the
maintenance of hyphae polarization. The resulting aber-
rant hyphal growth destabilizes the biofilm, and impairs
its maturation and three-dimensional organization.
Polarized hyphal extension strongly correlates with the
presence of specific structures in the hyphal tip. This
complex, a vesicle transit station, has a key role in the
hyphal morphogenesis, containing cell wall synthesis
enzymes, ribosomes, microtubules, and actin that are re-
quired for a polarized growth [17, 18]. Cheng co-
workers suggested that lipid rafts, sphingolipid-rich
plasma membrane domains, could be involved in the po-
larity apparatus. The inhibition of sphingolipid de novo
biosynthesis disrupts the actin organization at the tip,
and subsequently the normal hyphal growth [19]. The
disruption of actin patches at the hyphal tip could also
explain the aberrant multiple short hyphal branches.
The lipid rafts are also responsible of the selective inclu-
sion of plasma membrane-anchored proteins that par-
ticipate in the establishment and maintenance of the
polarized growth [20].
The aberrant multiple short hyphal branching ob-
served in this study could be related to disruption of
actin patches induced by Myriocin. Thus, it is conceiv-
able, given that sphingolipids are major components of
all eukaryotic membranes, that the sphingolipid synthe-
sis inhibitor Myriocin modulates the balance between
neo-synthesis and recycle of sphingolipids in membrane,
affecting rafts activities and signaling.
Moreover, other studies demonstrated that ceramide
synthesis promotes, while inhibition of ceramide synthe-
sis down regulates, the activity of sterol regulatory elem-
ent binding protein (SREBP) [21], responsible for
hypoxia adaptation, virulence and biofilm formation in
A. fumigatus [22, 23]. On-going studies in our laboratory
are currently investigating the hypothesis that Myriocin
could exert its powerful fungistatic activity by regulating
sphingolipids and ergosterol formation in A. fumigatus.
Being hypha development depending on massive pro-
duction of membranes, the inhibitor of sphingolipid syn-
thesis is highly effective in impairing fungal growth via
hypha elongation. This observation poses Myriocin as a
powerful fungistatic, abrogating the possibility to estab-
lish fungal biofilms and to enhance fungal sensitivity to
fungicidal drugs. The fungistatic activity has also been
confirmed by time-kill assay. Indeed, as for the conven-
tional antifungal drugs voriconazole and amphotericin B,
we observed a dose-dependent effect that did not reach
the arbitrary criterion determining fungicidal activity
(99.9 % or 3-log-unit decrease) [24].
Further studies, in vitro and in vivo, are needed to in-
vestigate the possible association of Myriocin with con-
ventional antifungals.
A contrasting evidence suggested that myriocin can
exert adverse effect on fungal infection treatment, due to
an overall immune response suppression induced in the
host that would eventually favor pathogen colonization
[25]. Although myriocin immunomodulatory activity
was proved [14, 25], it is important to point out that the
dose of the compound, used by Melo and coworkers
Fig. 2 Time-kill curves of Myriocin against Aspergillus fumigatus Af293.
To assess the possible fungicidal activity of Myriocin, the reference strain
Af293 was exposed to various concentrations of Myriocin, from 2 to 16
mg/L (a). For comparative purpose, two conventional antifungal drugs,
amphotericin B (AMB, b) and voriconazole (VRC, c) were tested
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(0.05 mg/L) in the Galleria mellonella model of Can-
dida infection, is about ten folds lower than the one ne-
cessary for antifungal activity, reported by us and by
others on fungal growth [26, 27]. It is evident that at low
dose, and systemically administered, the compound did
not have the chance to act directly on fungal growth but
it was probably sensed by hemolymph circulating hemo-
cytes, reducing the larvae defense response without af-
fecting Candida invasion. In line with this hypothesis,
the same authors questioned the possibility of a delayed
antifungal effect of myriocin, at a late phase of patho-
gens infection [25].
The morphological status of fungi plays an essential
role in the pathogenesis of fungal infections and in the
response to antifungal treatment. A. fumigatus has been
shown to become increasingly resistant to antifungal
agents throughout morphological differentiation. In par-
ticular, its ability to form a thick biofilm, characterized
by matrix production, results in a multifactorial resist-
ance phenomenon [28]. Our in vitro results confirm that
Myriocin exerts a powerful action in disrupting pre-
formed A. fumigatus biofilm, suggesting that targeting
sphingolipid metabolism could offer a new powerful tool
against biofilm forming infectious fungi.
With our data we basically propose myriocin as anti-
microbial agent in view of the need of pathogens to re-
produce themselves fast in the host and to establish
their colonies. This high metabolism rate phase of the
invasion is impaired by Myriocin. Further studies are
required to assess the dose, time and mode of treatment
to obtain maximal fungal toxicity with no side effect for
the host.
Finally, the encapsulation of antimicrobial agents into
solid lipid nanocarriers could be a potential strategy to
eradicate biofilms [29]. Our nanoparticles, due to their
lipophilic nature, ensure homogeneous delivery into the
deep biofilm structure, therefore decreasing the minimal
inhibition concentration (MIC) of the drug. Since nano-
carriers are known to provide drug stabilization and long
lasting release, ad hoc formulation can be envisaged in
anti-fungal therapies. Solid lipid nanocarriers size cut off
for optimal drug delivery depends on the mesh size of
the biofilm matrix and it has been tested for a few bac-
teria [30] and fungi, including Candida [31]. Our data
assess the advantages of using minimal size (30–50 nm)
solid lipid nanocarriers in fungal biofilm eradication,
exhibiting a fast spread of the drug into biofilm layers,
minimal effective dose and homogeneous delivery of
poorly soluble drugs. The use of SLN is recommended
with highly lipophilic drugs that hardly dissolve into ve-
hicle solutions. Nanovectors not only ensue solubility
but also efficacious membrane interaction and drug up-
load. In our case, the use of SLN improved significantly
drug introduction into deep biofilm layers.
Conclusions
This study demonstrated a direct antifungal activity of Myr-
iocin on A. fumigatus biofilm, suggesting that inhibition of
Fig. 3 Confocal laser scanning microscopy images of two-day-old biofilms of A. fumigatus strain Af293. The fungal biofilms were stained with
calcofluor white (blue staining). SLNs labelled with DiO (green staining) were then added and the penetrance measured after 2 h (upper panels)
and 6 h (lower panels). The rectangular micrographs on the sides (right panels) represent the x–z plane and y–z optical cross sections through
the thickness of the biofilms. The images shown (CLSM 20X) are representative of three independent experiments. Bar = 50 μm
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sphingolipid metabolism could represent a new target
to overcome biofilm-related fungal infections. Further
studies in vitro and in vivo are required to fully de-
fine the mode of action of this compound, especially
the downstream signaling pathway involved in the in-
hibition of hyphae germination.
Nanocarrier delivery of Myriocin was shown to rep-
resent a promising tool for drug delivery into the fun-
gal biofilms, with broader implications for healthcare
applications.
Methods
Myriocin stock solution preparation
Myriocin powder (Sigma Aldrich, Milan, Italy) was
weighted and dissolved in dimethyl sulfoxide by warm-
ing up at 37 °C, to a final concentration of 1 mM. Solu-
tion was sterile filtered and stored at -80 °C until used.
This stock solution was diluted in Roswell Park Memor-
ial Institute (RPMI) 1640 broth supplemented with 2 %
of glucose and buffered with morpholinepropanesulfonic
acid sodium salt.
Myriocin loaded-solid lipid nanoparticles (SLNs)
Myriocin-loaded nanocarriers (30–50 nm-diameter solid
lipid nanoparticles, SLNs) were prepared by Nanovector
srl (Turin, Italy), and a 1 mM Myriocin-SLNs stock solu-
tion was provided.
This solution was diluted in RPMI to achieve appro-
priate Myriocin concentrations. To study the SLNs per-
meation into the biofilm by confocal microscopy, we
used SLNs labeled with 3,3-dioctadecyloxacarbocyanine
perchlorate (DiO, Nanovector srl). A concentration of
100 mg/L was selected as a compromise to minimize
nanoparticles aggregation but to allow their visualization
at confocal microscope.
In vitro antifungal susceptibility testing
The reference strain Aspergillus fumigatus Af293 and 20
clinical strains of A. fumigatus were used in this study.
Clinical isolates were obtained from respiratory secre-
tions of cystic fibrosis patients, during routine follow up.
For the study, no additional data or samples were used.
Therefore, neither ethical approval nor patient consen-
sus was considered necessary.
Antifungal susceptibility testing was performed ac-
cording the EUCAST protocol for planktonic cells [32].
We tested various concentrations of Myriocin, ranging
from 0.25 to 64 mg/L. Readings were carried out after
Fig. 4 Ultrastructural imaging of A. fumigatus Af293 biofilm morphology
treated or not with Myriocin (4 mg/L). a 48h untreated biofilm: normal
fungal cells morphology (12000X original magnification -o.m.; Bar = 600
nm); b 4h post-Myriocin: the fungal cell showed some alterations of the
inner membrane that became non homogeneous (12000X o.m.;
Bar = 600 nm); c 24h post-Myriocin: the plasma membrane
showed several disorganized invaginations associated with cell wall
detachment (20000X o.m.; Bar = 400 nm); d 24h post-Myriocin: the
hyphae showed a cell wall collapsed, and a degenerated cytoplasm
highly vacuolarized; none of the cell organelles was recognizable.
(12000X o.m.; Bar = 600 nm); e 48h post-Myriocin: a large part of the
fungal cells is damaged and disrupted (12000X o.m.; Bar = 2.5 μm)
Fig. 5 Phytoceramides content in A. fumigatus Af293 biofilms. 24h-
preformed A. fumigatus biofilms were treated with Myriocin (4mg/L)
for 24 and 48h. Bars represent ceramide levels in untreated biofilm
(black bar) and in Myriocin-treated biofilm (stripes bar). Significance
was evaluated by t-test versus control untreated biofilm (**, p < 0.01)
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48 h of incubation at 37 °C. The minimum effective con-
centration (MEC), the lowest drug concentration result-
ing in aberrant hyphal growth, was assessed.
In vitro susceptibility testing on biofilm-organized iso-
lates was determined using a 96-well polystyrene plate,
as described by Pierce et al [33]. Briefly, A. fumigatus
strains were grown on Potato Dextrose agar (PDA)
slants for 5 days at 30 °C. Conidia were harvested by
adding 1.5 mL of PBS containing 0.025 % Tween-20
(v/v) and rocking gently. Conidia were then recovered and
counted by hemocytometer. 106 conidia/mL were grown
in RPMI 1640 at 37 °C to induce biofilm formation.
Biofilm-forming ability was quantified at 48 h by the 2,3-
bis(2-methoxy-4-nitro-5-sulfophenyl)- 2H-tetrazolium-5-
carboxanilide inner salt (XTT) reduction assay for
metabolically active cells and crystal violet (CV) stain-
ing for total biomass measurement. To test the activity
on biofilms, Myriocin, either alone or SLNs-loaded,
was added at different concentrations (from 2 to 64
mg/L) to 24 h preformed biofilms and incubated for
additional 24 h. The concentration of Myriocin that re-
sulted in a 50 % reduction of biofilm metabolic activity
was considered the sessile MIC. The experiments were
performed in triplicate.
Time-killing curve
Aliquots (10 mL) of the reference strain Af293 conidial
suspension (1x105–2x105 conidia/mL) were added to
10 mL of RPMI medium alone (control) and to ampho-
tericin B (concentration range 2–16 mg/L) voriconazole
(1–8 mg/L) or Myriocin (from 2 to 16 mg/L) diluted in
10mL RPMI. Cultures were placed on the shaker and
agitated at 37 °C. At predetermined time points (0, 2, 4,
and 24h) two samples of 0.1mL were removed from each
test suspension, serially diluted, and 0.1 mL aliquots were
spread in duplicate on PDA plates and incubated at 37 °C
for 48h. The time-kill curves were constructed by plotting
the colony forming units (CFU) per milliliter (expressed
as log10 CFU/mL) surviving at each time point in the
presence of various antimicrobial agents.
Confocal laser scanner microscopy (CLSM)
In order to understand the possible mechanism of the
direct antifungal activity, we performed microscopic ana-
lysis on the reference strain Af293, isolated from the re-
spiratory tract of a cystic fibrosis patient.
Fungal biofilms were formed on 18-mm-diameter
round coverslips (Sarstedt, Italy) seeded in a 24-well plate.
After incubation at 37 °C for 48 h, Myriocin 4 mg/L was
added and the biofilm incubated for further 24 h. The cov-
erslips were gently washed with PBS, stained with Calco-
fluor White (0.05 % v/v; Sigma), and mounted on a glass
coverslip for confocal laser-scanning microscope (Leica,
Inc.) visualization. Serial sections in the x-y plane were
obtained along the z-axis. Three-dimensional reconstruc-
tions of imaged biofilms were obtained using associated
software.
To determine whether Myriocin contained in SLNs
penetrates the fungal biofilm, 1 μL SLNs labeled with
DiO was added to a 48h-preformed biofilm and exam-
ined by CLSM, after 2 and 6 h, for the presence and
localization of the fluorophore.
Transmission electron microscopy (TEM)
For ultrastructural imaging, fungal biofilms were grown
and treated as previously described for CLSM. Biofilms
were fixed with 2.5 % glutaraldehyde in RPMI culture
medium for 4 h at room temperature, rinsed in the same
medium and then in double distilled water. Post-fixation
was carried out in 1 % OsO4 in H2O for 2 h, in order to
maintain also the lipid component of the membranes.
The specimens were embedded in 2 % agar in H2O and
then were dehydrated and embedded in epoxy resin. Ul-
trathin section were stained with uranyl, and observed in
a Zeiss EM900 electron microscope operated at 80kV
equipped with a 30 μm objective aperture.
LC-MS analysis
Fungal cells were grown in 6-well plate, treated with
Myriocin 4 mg/L for 24–48h, scraped and collected.
Total lipids were extracted from both planktonic and
biofilm-organized fungal cells by a two steps extraction.
Samples were extracted with chloroform/methanol (17:1,
v/v) for 120 min. The lower organic 17:1 phase lipid ex-
tract was collected. The remaining aqueous sample ma-
terial was re-extracted with chloroform/methanol (2:1,
v/v) for 120 min. The lower organic 2:1 phase lipid ex-
tract was collected. The lipid extracts, collected from
both extractions, were vacuum evaporated [34, 35]. Fi-
nally, the lipid extracts were dissolved in 100μL chloro-
form/methanol (1:2, v/v) fortified with the internal
standard, prepared and analyzed as previously described
by Munoz-Olaya et al. [36]. Total phospholipids were
quantitated and phytoceramide concentration was nor-
malized onto total Pi-lipids content of each sample as
previously described [37].
Statistical analysis
All results represent the mean of at least three independ-
ent experiments. Comparative results were statistically an-
alyzed using independent samples t-test (assuming equal
variance) and ANOVA with GraphPad software. A p value
of 0.05 was considered to be statistically significant.
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